Heart Failure Clinical Trials

Trials for someone you care about with heart failure.

Heart & Circulation

Recruiting Drug Device Behavioral Older adults Healthy volunteers

20 trials

Testing Omecamtiv Mecarbil (OM) against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Omecamtiv Mecarbil (OM). Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 11 more cities

Phase 3
2 groups
Sites in Edmonton, Kelowna and 11 more cities
Recruiting

Official title: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Heart Failure · Cytokinetics

Testing Vericiguat against a placebo for heart failure

Explore this study →

There are 3 groups in this study. Groups A and C receive one or more of: Vericiguat tablet and Vericiguat suspension. Group B, the placebo group, receives one or more of: Placebo tablet and Placebo suspension.

Sites in Edmonton, Sherbrooke and 1 more city

Phase 2
3 groups
Sites in Edmonton, Toronto and 1 more city
Recruiting

Official title: Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure · Merck Sharp & Dohme LLC

Testing Maridebart cafraglutide against a placebo for heart failure with preserved ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives Maridebart cafraglutide. Group B, the placebo group, receives Placebo.

Sites in Cambridge, Toronto and 16 more cities

Phase 3
2 groups
Sites in Edmonton, Winnipeg and 15 more cities
Recruiting

Official title: Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction · Amgen

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for heart failure.

Testing vicadrostat with empagliflozin against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives vicadrostat and empagliflozin. Group B, the placebo group, receives placebo and empagliflozin.

Sites in Montreal, Cambridge and 14 more cities

Phase 3
2 groups
Sites in Cambridge, Hamilton and 14 more cities
Recruiting

Official title: A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure · Boehringer Ingelheim

Testing vicadrostat with empagliflozin against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives vicadrostat and empagliflozin. Group B, the placebo group, receives Placebo and empagliflozin.

Sites in Québec, Brossard and 12 more cities

Phase 3
2 groups
Sites in Cambridge, Greater Sudbury and 12 more cities
Recruiting

Official title: A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Heart Failure · Boehringer Ingelheim

Testing Low Dose PF-07328948 against a placebo for heart failure

Explore this study →

There are 4 groups in this study. Group A, the placebo group, receives Placebo. Group B receives Low Dose PF-07328948. Group C receives Medium Dose PF-07328948. …and 1 more groups.

Sites in Greater Sudbury, Winchester and 10 more cities

Phase 2
4 groups
Sites in Richmond, Halifax and 9 more cities
Recruiting

Official title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure · Pfizer

Testing Baxdrostat and dapagliflozin for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Baxdrostat and dapagliflozin. Group B receives Placebo and dapagliflozin.

Sites in Toronto, Calgary and 27 more cities

Phase 3
2 groups
Sites in Calgary, Sherwood Park and 26 more cities
Recruiting

Official title: Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Heart Failure · AstraZeneca

Comparing 3 approaches for heart failure and impaired kidney function

Explore this study →

There are 3 groups in this study. Group A receives balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg. Group B receives balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg. Group C, the comparison group, receives dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin.

Sites in Montreal, Cambridge and 20 more cities

Phase 3
3 groups
Sites in New Westminster, North Vancouver and 19 more cities
Recruiting

Official title: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function · AstraZeneca

Testing CDR132L against a placebo for heart failure

Explore this study →

There are 4 groups in this study. Groups A, B and C receive CDR132L. Group D, the placebo group, receives Placebo.

Sites in Hamilton, Toronto and 6 more cities

Phase 2
4 groups
Sites in Vancouver, Brampton and 6 more cities
Recruiting

Official title: A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Heart Failure · Novo Nordisk A/S

Testing Colchicine with Thiamine Mononitrate against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives one or more of: Colchicine 0.5 MG and Colchicine placebo. Group B receives Thiamine Mononitrate 300 mg.

One site, in Hamilton

Phase 3
2 groups
One site, in Hamilton
Recruiting

Official title: COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

Heart Failure · Hamilton Health Sciences Corporation

Testing HJB647 low dose against a placebo for heart failure with reduced ejection fraction

Explore this study →

There are 3 groups in this study. Group A, the placebo group, receives Placebo. Group B receives HJB647 low dose. Group C receives HJB647 high dose.

One site, in Montreal

Phase 1
3 groups
One site, in Montreal
Recruiting

Official title: A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction · Novartis Pharmaceuticals

Testing Elecoglipron for heart failure with preserved ejection fraction (hfpef)

Explore this study →

There are 2 groups in this study. Group A receives Elecoglipron. Group B, the comparison group, receives Placebo.

Sites in London, Markham and 14 more cities

Phase 3
2 groups
Sites in Barrie, Etobicoke and 13 more cities
Recruiting

Official title: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Heart Failure With Preserved Ejection Fraction (HFpEF) · AstraZeneca

Testing Finerenone against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone. Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 12 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 11 more cities
Recruiting

Official title: A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Heart Failure · Colorado Prevention Center

Testing Finerenone with Empagliflozin for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone and Empagliflozin. Group B receives no study treatment and is followed for comparison.

Sites in Toronto, Edmonton and 6 more cities

Phase 3
2 groups
Sites in Edmonton, Surrey and 5 more cities
Recruiting

Official title: A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Heart Failure · Colorado Prevention Center

Testing Midodrine for heart failure with reduced ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives Midodrine Oral Tablet. Group B receives no study treatment and is followed for comparison.

One site, in Ottawa

Phase 2
2 groups
One site, in Ottawa
Recruiting

Official title: Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension

Heart Failure With Reduced Ejection Fraction · Ottawa Heart Institute Research Corporation

Testing Combined Epoprostenol Sodium & Milrinone against a placebo for right heart failure

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives Normal saline. Group B, the comparison group, receives Combined Epoprostenol Sodium & Milrinone.

One site, in Montreal

Phase 2
2 groups
One site, in Montreal
Recruiting

Official title: Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

Right Heart Failure · Montreal Heart Institute

Testing Finerenone against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone. Group B, the placebo group, receives Placebo.

Sites in Edmonton, Toronto and 10 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 9 more cities
Recruiting

Official title: A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Heart Failure · Colorado Prevention Center

Testing Levocarnitine for heart failure

Explore this study →

Everyone in this study is in one group and receives Levocarnitine.

One site, in London

Early Phase 1
1 group
One site, in London
Recruiting

Official title: Oral Carnitine in Heart Failure Patients

Heart Failure · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Testing Lumacaftor against a placebo for heart failure with reduced ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives Lumacaftor 200 MG. Group B, the placebo group, receives Placebo.

2 sites in Toronto

Phase 2
2 groups
2 sites in Toronto
Recruiting

Official title: Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients

Heart Failure With Reduced Ejection Fraction · Qanatpharma AG

Testing Vericiguat for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Vericiguat. Group B receives no study treatment and is followed for comparison.

Sites in Calgary, Edmonton and 2 more cities

Phase 2
2 groups
Sites in Calgary, Edmonton and 2 more cities
Recruiting

Official title: COgnitioN With VERiciGuat Evaluation in Heart Failure

Heart Failure · University of Alberta

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Heart Failure trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.